Valuation: MedinCell

Market Cap 880M 1.02B 821M 754M 1.42B 96.8B 1.44B 9.64B 3.78B 48.53B 3.82B 3.73B 160B P/E 2027 *
408x
P/E 2028 * 51.5x
Enterprise Value 865M 1B 807M 741M 1.39B 95.17B 1.41B 9.48B 3.71B 47.71B 3.75B 3.67B 158B EV / Sales 2027 *
19.6x
EV / Sales 2028 * 14.4x
Free-Float
66.02%
Yield 2027 *
-
Yield 2028 * -
Manager TitleAgeSince
Chief Executive Officer 62 2003-01-08
Director of Finance/CFO 52 2023-08-31
Chief Tech/Sci/R&D Officer 67 2022-05-08
Director TitleAgeSince
Director/Board Member 62 2003-01-08
Chairman - 2024-03-12
Director/Board Member - 2016-05-24
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.02B
-0.52%+3.21%+85.02%+161.12% 1,057B
+0.88%+1.13%+51.13%+49.76% 625B
+0.89%-1.95%+23.73%+63.67% 435B
+0.71%+3.87%+47.45%+38.68% 363B
+0.64%-0.49%+35.39%+40.21% 296B
+0.39%-5.83%+8.64%+9.28% 249B
+1.51%+6.69%+44.34%+62.47% 222B
+3.92%-0.46%-1.21%-44.09% 209B
+1.80%+2.30%+20.79%+65.13% 165B
Average +1.02%+0.87%+35.03%+49.58% 402.31B
Weighted average by Cap. +0.66%+1.22%+48.34%+75.33%

Financials

2027 *2028 *
Net sales 44.14M 51.01M 41.21M 37.82M 71.1M 4.86B 72.17M 484M 190M 2.43B 192M 187M 8.05B 58.92M 68.09M 55M 50.48M 94.9M 6.48B 96.33M 646M 253M 3.25B 256M 250M 10.75B
Net income 667K 770K 622K 571K 1.07M 73.35M 1.09M 7.3M 2.86M 36.77M 2.89M 2.83M 122M 13.33M 15.4M 12.44M 11.42M 21.46M 1.47B 21.79M 146M 57.23M 735M 57.82M 56.56M 2.43B
Net Debt -14.87M -17.18M -13.88M -12.74M -23.94M -1.64B -24.3M -163M -63.84M -820M -64.5M -63.1M -2.71B -30.53M -35.29M -28.5M -26.16M -49.18M -3.36B -49.92M -335M -131M -1.68B -132M -130M -5.57B
Logo MedinCell
MedinCell S.A. is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqTM). As of March 31, 2026, the company had a portfolio of a product in phase III clinical development and 3 products in preclinical development.
Employees
-
Trader
Investor
Global
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
24.50EUR
Average target price
34.51EUR
Spread / Average Target
+40.86%

Quarterly revenue - Rate of surprise